Patient Case #3: 32-Year-Old Male With AD
Expert dermatologists review a final case about a 32-year-old male with AD, highlighting systemic therapy as first-line treatment.
Counseling AD Patients on Injection Concerns
Elizabeth Swanson, MD, shares pearls on how to communicate with AD patients who are uncertain about treatment through self-administered injection.
Guidelines and Recommendations for Therapies in AD
Experts in dermatology review recommendations for systemic therapies and JAK inhibitors in the management of AD and other factors that guide treatment selection.
Patient Case #2: Adolescent Male With AD
Jonathan I Silverberg, MD, PhD, MPH; Elizabeth Swanson, MD; Brad Glick, DO, MPH, FAOCD; and Andrew Blauvelt, MD, MBA, discuss their initial impressions of an adolescent patient with AD, focusing on systemic therapy.
Patient Case #1: AD Treatment Options
Elizabeth Swanson, MD; Brad Glick, DO, MPH, FAOCD; and Andrew Blauvelt, MD, MBA, highlight treatment options for a specific patient with AD, focusing on dupilumab.
Treatment of AD in Clinical Practice
Experts in dermatology review clinical trials for AD treatment and how this data translates into their own practices.
Use of Dupilumab in AD
Expert dermatologists review the use of dupilumab for the treatment of AD, focusing on the once-monthly shot as a factor in selection.
Patient Case #1: AD Treatment Approaches
Elizabeth Swanson, MD, and Brad Glick, DO, MPH, FAOCD, share treatment approaches for pediatric patients with AD.
Patient Case #1: 6-Year-Old Male Patient With Moderate AD
Expert dermatologists present and share initial impressions of a patient case for a 6-year-old male with AD, highlighting the impact of sleep deprivation.
Switching Treatment in AD
Jonathan I Silverberg, MD, PhD, MPH; Elizabeth Swanson, MD; Brad Glick, DO, MPH, FAOCD; and Andrew Blauvelt, MD, MBA, review factors that lead to switching therapies in AD, focusing on monotherapies vs combination therapy.
Time to Treatment Response in AD Treatment Selection
Experts in dermatology comment on how often quickness of response to therapy determines treatment selection for teenaged patients with AD.
Treatment Selection for AD
Expert dermatologists discuss treatment selection for short-term rescue vs long-term maintenance therapy.
Use of Systemic vs Topical Treatment of AD
Andrew Blauvelt, MD, MBA, reviews systemic vs topical treatment of AD, discussion patient preferences as a factor for treatment selection.
Treatment Landscape for Atopic Dermatitis (AD)
Experts in dermatology discuss the rapidly expanding treatment landscape of atopic dermatitis and how these new treatment options have changed the management of AD.
Optimizing the Treatment of Atopic Dermatitis
Andrew Blauvelt, MD, MBA, shares clinical pearls for the management of atopic dermatitis with systemic therapy.
Unmet Needs in Atopic Dermatitis Management
An expert dermatologist provides insight on unmet needs in clinical trial endpoint measurements that would improve the management of atopic dermatitis.
Understanding Dupilumab Treatment Response in Atopic Dermatitis
Dr Andrew Blauvelt discusses the relevance of dupilumab treatment response as seen in the LIBERTY AD OLE and LIBERTY AD CHRONOS studies and shares his approaches to improving atopic dermatitis management.
LIBERTY AD CHRONOS Study in Atopic Dermatitis
Andrew Blauvelt, MD, MBA, reviews clinical implications from the phase 3 LIBERTY AD CHRONOS study examining the efficacy of dupilumab plus topical corticosteroids in adult patients with moderate to severe atopic dermatitis.
Real-World Implications of Dupilumab Treatment in Atopic Dermatitis
An expert dermatologist provides key takeaways and the real-world significance of dupilumab use for the treatment of atopic dermatitis.
LIBERTY AD OLE Study in Atopic Dermatitis
Dr Andrew Blauvelt reviews key highlights and clinical implications from the LIBERTY AD OLE study assessing the effect of long-term dupilumab treatment on efficacy improvements in adults with moderate to severe atopic dermatitis.
Atopic Dermatitis: Evolution of Care
Andrew Blauvelt, MD, MBA, reviews recent advances in the therapeutic landscape for moderate to severe atopic dermatitis.
2 Clarke Drive Cranbury, NJ 08512